+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Evidence of parasympathetic activity of the angiotensin converting enzyme inhibitor, captopril, in normotensive man

Clinical Science 68(1): 49-56

Evidence of parasympathetic activity of the angiotensin converting enzyme inhibitor, captopril, in normotensive man

Captopril (50 mg orally) produced a significant fall in systolic and diastolic blood pressure in 6 normotensive Na replete subjects, without a rise in heart rate. On captopril, there was no change in the expected normal increase in heart rate on standing. Supine plasma noradrenaline [norepinephrine] was not reduced by captopril and normal postural increases were maintained. Atropine (0.04 mg/kg i.v.) reduced the difference in blood pressure change between captopril and placebo. Facial immersion in water produced a bradycardia. This change was abolished by atropine and attenuated both by captopril and edrophonium (10 mg i.v.), a cholinesterase inhibitor. Lying down after 6 min standing produced an immediate transient tachycardia, which was abolished by atropine and attenuated by captopril. Blood pressure and heart rate rose after a cold pressor test on both captopril and placebo. The tachycardia during the Valsalva maneuvre was inhibited by edrophonium and to a lesser extent by captopril. The effects of captopril and edrophonium were additive. Parasympathetic activity of captopril may contribute to its hemodynamic profile.

(PDF same-day service: $19.90)

Accession: 005411630

PMID: 3880523

DOI: 10.1042/cs0680049

Related references

Effects of captopril, an angiotensin-converting enzyme inhibitor, in normotensive sodium-replete volunteers. Journal of Cardiovascular Pharmacology 4(3): 381-387, 1982

Effects of angiotensin converting enzyme inhibitors captopril and cv 3317 n n 1 s ethoxycarbonyl 3 phenylpropyl l alanyl n indan 2 yl glycine hydrochloride on angiotensin converting enzyme activities in normotensive rats. Japanese Journal of Pharmacology 36(SUPPL): 303P, 1984

Responses of blood pressure and angiotensin-converting enzyme activity to acute captopril administration in normotensive and hypertensive rats. Endocrinology 108(2): 536-544, 1981

Effects of benazepril, an angiotensin-converting enzyme inhibitor, combined with CGS 35066, a selective endothelin-converting enzyme inhibitor, on arterial blood pressure in normotensive and spontaneously hypertensive rats. Clinical Science 103 Suppl 48: 363s-366s, 2002

Prevalence of the angiotensin I converting enzyme insertion/deletion polymorphism, plasma angiotensin converting enzyme activity, and left ventricular mass in a normotensive Chilean population. American Journal of Hypertension 12(7): 697-704, July, 1999

Non-sulfhydryl-containing angiotensin-converting enzyme inhibitor (MK421): evidence for role of renin system in normotensive subjects. British Medical Journal 283(6288): 401-403, 1981

Murine Recombinant Angiotensin-Converting Enzyme 2 Effect on Angiotensin II-Dependent Hypertension and Distinctive Angiotensin-Converting Enzyme 2 Inhibitor Characteristics on Rodent and Human Angiotensin-Converting Enzyme 2 Renin-Angiotensin-Aldosteron. 2012

Tissue angiotensin converting enzyme activities and their inhibition by the converting enzyme inhibitor cilazapril differ among normotensive and hypertensive rats. Journal of Hypertension 6(SUPPL 4): S729-S730, 1988

The effects of an angiotensin converting enzyme inhibitor captopril on vascular phospholipase c activity in spontaneously hypertensive rats. Japanese Circulation Journal 52(9): 911-912, 1988

Determination of the inhibitory activity of angiotensin-converting enzyme inhibitor captopril by high performance capillary electrophoresis. Yao Xue Xue Bao 38(11): 843-845, 2004